Glucagon and GLP-1 receptor co-agonist
Mazdutide 4.5 mg subcutaneous once weekly
MAZD_SC_4p5MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.46 (0.01 to 20.59) | 0.48 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.39 (0.00 to 13.34) | 0.71 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.23 (0.00 to 5.39) | 0.73 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.07 (0.00 to 0.64) | 0.93 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.34 (0.00 to 10.69) | 0.75 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.57 (1.13 to 5.56) | 0.51 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.93 (1.06 to 8.04) | 0.47 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 5.25 (2.63 to 10.98) | 0.09 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.90 (0.05 to 13.66) | 0.46 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 0.90 (0.05 to 14.65) | 0.48 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.69 (0.01 to 52.19) | 0.50 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -4.95 (-14.30 to 5.32) | 0.58 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -10.53 (-17.85 to -2.01) | 0.67 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 44.07 (3.44 to 190) | 0.85 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 31.82 (3.99 to 207) | 0.84 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 9.08 (1.43 to 73.39) | 0.60 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 5.70 (0.80 to 56.88) | 0.16 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 4.90 (0.18 to 151) | 0.32 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.36 (1.56 to 14.30) | 0.41 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.12 (1.53 to 20.38) | 0.43 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.20 (0.89 to 5.49) | 0.44 |
Trials
- NCT04965506A Randomized Phase II Study to Evaluate the Efficacy and Safety of IBI362 Versus Placebo and Dulaglutide in Chinese Patients With Type 2 Diabetes2021 · 252 randomized · 20 weeks
- NCT04904913A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Chinese Overweight and Obese Subjects2021 · 248 randomized · 24 weeks
- NCT04466904A Multiple Dose Human Tolerability and Pharmacokinetic Study of IBI362 in Chinese Patients With Type 2 Diabetes Mellitus and Poor Glycemic Control2020 · 43 randomized · 12 weeks